Embryo Gene Editing

Author’s disclosure: I have no current or anticipated financial or medical interest in embryo editing. I simply believe the bioethics consensus is wrong.

Humanity has mastered the technology to edit genes. We use it to cure disease. Most gene therapies, however, struggle to work without causing incidental harm. The human body has trillions of cells of many types. An edit must reach enough of the right cells to work, avoid the incidental cells, and change only the intended DNA sequence in the cells it does reach. A fertilized egg, in contrast, begins as a single cell, the zygote. When the parents are known carriers of a defined mutation, that mutation can be corrected at the one-cell stage before the zygote divides into an embryo. An edit at this stage is carried into every cell of the future human body. It is more precise and more complete than any edit attempted at a later stage of life.

A community of professionals claims that editing embryos is unethical in many or most cases. This essay refutes their most common rationales. Every medical intervention carries risk. The ethical question is whether the risks of acting exceed the risks of inaction. The decision to prevent a serious genetic disease in a future child belongs to the parents and their physicians, not to a panel of philosophers or a society-wide referendum.

A complete ethical analysis for using any new technology has four parts:

1. The benefits of acting.

2. The harms of acting.

3. The benefits of not acting.

4. The harms of not acting.

When the bioethics community publishes long reports on the risks of embryo editing without comparable attention to the certain suffering of children born with preventable genetic diseases, it has performed only one quarter of a complete analysis. The harms of inaction are not speculative. They are measured in body counts every day.

Critics often invoke eugenics as a warning against embryo editing. The comparison deserves serious reconsideration.

The eugenics movement of the early twentieth century was not, in the minds of its proponents, evil. They understood it as the prevention of inherited disease and disability. Leading academics, jurists, and physicians supported it. State laws authorized the forced sterilization of more than sixty thousand Americans in pursuit of what its supporters genuinely believed was a healthier society.

The lesson of that history is not that disease prevention is dangerous. The lesson is that the prevailing academic philosophy of what is ethical changes over time, and that confidence in the current consensus is not evidence the consensus is right. The eugenicists were sure. They were also wrong.

What’s the same between then and now is not what gets restricted but who gets coerced. A century ago, the prevailing academic philosophy authorized the state to take reproductive choices away from people who wanted children. Today, the prevailing academic philosophy would authorize the state to take reproductive choices away from people who want healthy children. The current fashion of ethics has reversed. The coercive intent remains.

A related concern is that preventing genetic disease through embryo editing implies that the lives of people with disabilities are less valuable. This objection deserves serious engagement.

People born with disabilities, past, present, or future, deserve full societal inclusion, accommodation, and equal respect. However, preventing a condition does not devalue people already living with it. Embryo editing represents an expansion of compassion by giving a family a choice to avoid preventable disabilities before they begin. Societies routinely pursue prevention, through vaccination, newborn screening, or corrective surgery, without implying that those who experience the condition are lesser.

Some critics speak of “the human genome” as a single sacred entity to be preserved. The phrasing assumes a single common definition of our species. There is no such thing. Eight billion people are alive today, each with a different genome.

Human genomes have changed substantially over recorded history. Lactase persistence into adulthood is a recent mutation. So are dozens of variants that adapt populations to altitude, diet, and pathogen exposure. Correcting one disease-causing letter in a three billion letter document does not assault human essence.

Bioethicists sometimes object that descendants of an edited person would inherit genetic risks without their consent. Every parent already makes genetic decisions on behalf of their future children without the child’s consent. Decisions about parental age, lifestyle, and mate selection are already profound genetic choices. Intergenerational consent is impossible, and no society requires it.

The proper ethical standard is one of responsible stewardship. Parents should reduce foreseeable harm to their children when the evidence supports doing so. Embryo editing fits this existing framework.

The objection also ignores symmetry. Descendants of unedited carriers of serious diseases, such as Huntington’s, inherit the near-certainty of devastating illness without consent. By contrast, descendants of edited individuals would inherit only a much smaller and diminishing risk of unintended effects. Embryo editing increases net autonomy across generations by freeing future children from the tyranny of a known pathogenic variant. The argument otherwise is logically backwards.

Some commissions hold that clinical use should not proceed without broad societal consensus. That is unattainable.

The United States lacks consensus on the ethics of most important technologies. We have no consensus on nuclear energy, on self-driving cars, on abortion, on vaccines, or on preimplantation genetic testing, which opponents themselves cite as an alternative to editing. A consensus standard never met for any other technology is not a standard. It is a permanent ban dressed in procedural language.

The consensus condition is also ill defined. Can editing be ethical in China if consensus exists there but not in the United States? Can it be ethical in New Hampshire, the “live free or die” state, but not across the border in Massachusetts? The relevant quantum of society is the family faced with the diagnosis.

A related condition demands adequate international governance before clinical use proceeds. No such governance body exists. None is foreseeable. The proposal amounts to another permanent ban.

The United States Food and Drug Administration does not require international governance before approving cancer drugs, surgical techniques, or vaccines. New technologies and their governance always develop in parallel, not sequentially.

Many opponents claim that international governance is needed to prevent rogue actors. He Jiankui produced gene edited babies in China in 2018. The Chinese government, one of the most controlling in the world, neither prevented his work nor yet discloses the resulting children’s health status. History disproves the idea that a global body could prevent rogue actors.

If a reasonably permissive legal regime had been in place in either the United States or China, He Jiankui surely would not have experimented outside a clinical framework, in secret, and without informed consent.

A related claim holds that authoritarian regimes will use embryo editing for military purposes if democratic countries permit it for disease prevention. Authoritarian regimes do not condition their military programs on the health policies of democracies. Democracies maintain influence over how a technology gets used by being competent at it without ceding it to authoritarian states.

An honest case for embryo editing must name the technical risks. Four matter most.

The first is off-target effects. Editing enzymes aim at a specific sequence in the genome but can accidentally change other sequences that resemble the target. An off-target edit might alter a regulatory region, disrupt a developmental pathway, or disable a tumor suppressor gene thereby causing cancer. Newer chemistries, including base editing and prime editing, reduce off-target rates substantially, and scientists, armed with AI, are racing to make ever better editors.

The second is mosaicism. If the embryo begins cell differentiation in the zygote stage before the edit completes in all cells, the resulting child’s organs will carry some edited and some unedited genes. The disease-causing gene might persist in some organs and cause the disease unexpectedly. If the sperm or eggs are formed from unedited cells, the child can pass the disease to their own children despite appearing free of it. Editing earlier in development and optimizing reagent kinetics reduce mosaicism. Mosaicism also occurs naturally in essentially every pregnancy and is usually harmless. Treating it as an absolute disqualifier ignores its natural prevalence and its declining likelihood under newer editing methods.

The third is chromosomal damage. First-generation CRISPR cuts both strands of DNA. The following repair process sometimes produces large deletions, translocations, or chromothripsis.

The fourth is unknown long-term consequences. A gene typically participates in multiple biological pathways. A variant that prevents one disease might cause another. Effects might not appear until decades after the edit. Current biological models cannot predict every consequence of every change.

Most errors introduced by modern editing techniques would either result in a failure to implant or have no meaningful effect on the health or quality of life of the child or their descendants. Whole-genome sequencing can detect the majority of remaining issues. In the rare cases where an error persists, the same editing technology could correct it in the next generation through in vitro fertilization (IVF). The risks of editing are therefore real, but they are bounded, manageable, and continuing to shrink with technological progress.

Bioethicists argue for restriction until evidence shows safety across a large cohort of human embryos with no off-target effects, no mosaicism, no chromosomal damage, and whole genome sequencing for confirmation. That standard is unreasonable.

No medical intervention has zero risk. Hospitals perform many higher-risk procedures every day on patients with serious conditions, including somatic gene therapies for some of the same diseases that could be prevented by embryo editing. Embryo editing is already safer than many of them.

Natural reproduction alone carries a significant rate of random genetic changes that occur spontaneously. These baseline risks are comparable to or higher than those associated with embryo editing.

The appropriate standard under a proper ethical framework is that the risks are low enough that parents can reasonably weigh them against the benefits of preventing disease. Estimating the risks is the job of embryologists and clinicians. Choosing what level of risk to accept is the right of the affected family, fully informed by their physicians. Academics don’t belong in the decision process.

Several proposals would permit editing only for serious monogenic diseases with severe morbidity or premature death. The restriction sounds principled. It is not.

The word “serious” has no agreed definition. Huntington’s disease clearly qualifies. Hereditary breast cancer caused by BRCA1 mutations causes severe morbidity, premature death, and chemotherapy and surgery for those who survive. Yet the proposed rule excludes BRCA1 on two grounds. The first is that breast cancer is polygenic. The second is that a BRCA1 mutation makes the disease highly likely but not certain.

Regarding the polygenic objection, a BRCA1 mutation raises lifetime breast cancer risk to roughly seventy percent. A woman who has watched her mother and sister go through chemotherapy is not making a frivolous choice when she asks whether her daughter must inherit the same odds. Other genes also contribute, but BRCA1 dominates the risk in these families. Editing it confers protection.

Regarding the certainty objection, modern medicine has never required certainty for any other intervention. Doctors prescribe statins to people with elevated cholesterol who might never have a heart attack. Surgeons perform prophylactic mastectomies on women with BRCA mutations who might never develop cancer. Absolute certainty has never been the standard for medical prevention.

No ethical principle mandates a “serious monogenic disease” rule. It is arbitrary, and patients pay the cost of it.

Preimplantation genetic testing (PGT) involves creating embryos, screening them, discarding affected ones, and implanting unaffected ones. Many opponents of editing offer PGT as an alternative. The logical inconsistency is sharp. PGT is far more invasive of the moral status of embryos than editing is. It accepts the destruction instead of treatment of embryos with disease-causing variants.

Even accepting PGT as an alternative, it is insufficient. A woman who has survived breast cancer and chemotherapy often has reduced ovarian reserve. She might have only a few viable eggs, and PGT might not yield an unaffected embryo. The proposed rule tells her that she may not spare her daughter the same disease, the same chemotherapy, and the same decision about prophylactic mastectomy that she herself faced.

Bioethicists raise a slippery slope objection. If society permits embryo editing for serious monogenic diseases, it will inevitably lead to editing for polygenic conditions, then milder diseases, then non-medical traits, and ultimately to enhancements that entrench a cruel, class-stratified society.

This concern is overstated and inconsistently applied. The same slippery slope argument applies equally to PGT. In practice, doctors already use PGT to screen not only for monogenic diseases but also for polygenic risk scores, non-disease traits, and sex selection. Despite these expansions, governments have successfully drawn and adjusted regulatory lines as new cases emerged. We routinely debate and regulate other morally contested technologies and practices such as cosmetic surgery, cognitive enhancers, and performance steroids. The same measured approach of clear rules combined with democratic oversight can be applied to embryo editing.

The absence of consensus on where to draw the line is not a reason to prohibit an activity that clearly sits on the acceptable side of it.

Equity is a serious concern. If only wealthy families can afford embryo editing, it will widen existing health and socioeconomic disparities. Three responses follow.

First, prevention is cheaper than treatment. A round of IVF with embryo editing might cost twenty thousand dollars in the United States. An approved gene therapy for a serious genetic disease might cost two million dollars and require lifelong supportive care. A health system that pays for the latter and restricts the former is not improving equity. It is locking in the most expensive option to the benefit of the pharmaceutical industry.

Second, equitable access requires public insurance coverage. Medicaid does not currently cover IVF, PGT, or embryo editing for couples carrying serious heritable disease. The current restrictions on IVF coverage are themselves a serious equity problem and merit active advocacy for coverage expansion rather than impeding a form of preventative care.

Third, withholding a technology does not improve equity. Making it available does. Medical innovations follow a pattern. They start expensive and available to the wealthy, then spread as costs fall and coverage expands. IVF itself followed that path. Banning any technology until it is universally affordable would have prevented most of the great medical advances of the last century.

The bioethics community that produces the major commissions, statements, and guidelines on embryo editing has three structural features worth naming.

First, much of the field draws funding, directly or indirectly, from pharmaceutical companies that sell drugs to people with genetic diseases. Embryo editing could prevent many of those diseases. This is not an accusation against any individual. It describes the field’s funding ecology, and it deserves consideration whenever bioethicists pronounce on whether prevention is permitted.

Embryo editing startups have profit motives too. But pharmaceutical companies profit when children inherit genetic diseases. Editing companies profit when families prevent them. The incentives run in opposite directions.

Second, the field operates at a distance from the people it wishes to regulate. Bioethicists write in the abstract. Few have spent significant time in homes where a child declines from spinal muscular atrophy or had to tell a parent that their newborn has Tay-Sachs. The bodily degradation that accompanies serious genetic disease happens behind closed doors. It does not appear in the literature.

Third, the major commissions on heritable genome editing have included professors, lawyers, and scientists. A topic framed as civilization-shaping draws attention, benefiting the careers of those whose professions lie in writing. However, the commissions have not included the people whose lives their recommendations would most affect. A panel that excludes the affected population and then pronounces on that population’s reproductive choices has a legitimacy problem regardless of the quality of its reasoning.

Embryo editing is a uniquely powerful technology. Reasonable people can differ on the threshold of acceptable risk. However, the bioethics community would place the entire burden for allowability on those who want to offer this disease-preventing technology. They demand safety standards no reproductive technology has ever met. They demand consensus that no society has ever achieved. They demand supervision by institutions that do not exist. They demand restriction to a category that no one has defined. The cumulative effect would be a de facto indefinite moratorium.

Their analysis contradicts the Hippocratic obligation to weigh both action and inaction. A genuine ethics of embryo editing asks whether the near-certain benefits exceed the diminishing risks. In case after case, they do.

A child born with a serious genetic disease never consented to inherit it. An edited child will live to make their own choices, including the choice of how to pass their own genome to the next generation. Editing expands future autonomy. It does not constrain it.

Real families with known genetic diseases will soon face difficult decisions about whether to use embryo editing to spare their children. They will make those decisions in clinics, with their physicians, on the basis of family history, medical evidence, and personal values. The choice is rightfully theirs.

The role of policy is to ensure that choice is informed, safe, and available. The role of policy is not to block reproductive choice on the recommendation of philosophers.